TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has made a game-changing breakthrough in their quest to more effectively treat cancer! Their lead therapeutic candidate, TTX-MC138, has had its data published in the June 1 supplemental issue of the Journal of Clinical Oncology. This incredible new development was presented at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), leading the way in truly transformative cancer treatments!
TransCode’s new research reveals a transformative discovery – that inhibiting microRNA-10b, the therapeutic target of TTX-MC138, in breast cancer cells can impede the proliferation of cancer stem cells, leading to reduced tumor growth and decreased metastasis.
This marks a major breakthrough in the medical field, as cancer stem cells are notorious for their critical role in the development of cancer, as well as its recurrence and resistance to therapy. By utilizing TTX-MC138 to inhibit tumor-promoting cancer stem cells, the effects of breast cancer can be drastically improved in patients with recurrent and resistant diseases.
TTX-MC138 is an innovative therapy that has the potential to revolutionize the way we treat cancer. The drug, which is designed to inhibit the oncogenic microRNA-10b, has shown remarkable results in preclinical models of pancreatic adenocarcinoma and human breast cancer.
Results of a study in an animal model of pancreatic cancer showed a complete response rate of 40% when administered as a monotherapy, and a case study of spontaneous feline mammary carcinoma revealed significant efficacy. This promising treatment could offer hope to those living with advanced solid tumors, such as breast cancer.
TransCode Therapeutics is taking the leap into a first-in-human clinical trial with its promising therapeutic candidate, TTX-MC138, for advanced solid cancers. Up to twelve brave souls will receive a single dose of this radiolabeled agent, followed by noninvasive imaging to assess the amount delivered and the effective pharmacokinetics.
Such valuable data gathered could have crucial implications in determining the optimum dose, timing, and safety of TTX-MC138 in later stage trials. This trial is no mere formality—it could be the key to unlocking therapeutic effects in glioblastoma and other advanced malignancies.
An exciting breakthrough announced in the Journal of Clinical Oncology by TransCode Therapeutics’ CEO Michael Dudley has shed light on the astounding effectiveness of TTX-MC138 in multiple, preclinical cancer models. Incredibly, complete responses with no recurrence have been seen in the metastatic cancer setting – an immense development in the field of cancer research.
About TransCode Therapeutic
TransCode is out to revolutionize the field of RNA oncology with a range of therapeutic drug candidates designed to target a variety of tumors and improve patient outcomes. The company’s lead candidate, TTX-MC138, takes aim at metastatic cancer which is believed to cause 90% of all cancer deaths. It has the potential to improve clinical outcomes in breast, pancreatic, ovarian and colon cancer, glioblastomas and more.
TransCode also offers three cancer-agnostic programs: TTX-RIGA, TTX-CRISPR and TTX-mRNA. Together, these therapies are focused on driving immune responses, repairing or eliminating cancer-causing genes and creating cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode is determined to help more people beat cancer, one RNA therapy at a time.
Forward-Looking Statements
TransCode is proud to announce its preclinical study of TTX-MC138 in breast cancer and other tumor types, and to share its expectations of future clinical results for its therapeutic candidates, as well as the potential for RNA therapeutics to treat cancer. With a planned first-in-human study of TTX-MC138, TransCode is striving to demonstrate proof-of-mechanism, while filing regulatory filings and conducting clinical trials with hopes of a positive outcome.
However, a variety of risks remain including financial difficulties, competition in the industry, the complexities of obtaining, maintaining, and protecting intellectual property, and the uncertainty posed by the COVID-19 coronavirus. Despite these challenges, we remain optimistic about TransCode’s future and its development of its TTX technology platform.